Dermatology

In a new post hoc analysis of 4 pivotal clinical studies in atopic dermatitis and prurigo nodularis, nemolizumab was shown to improve symptoms.

Topical steroid withdrawal remains a controversial topic in the dermatology field, given the lack of necessary data.

Cosmo Pharmaceuticals released pivotal phase 3 findings on clascoterone treatment, a potential first-in-class medication designed to target androgenetic alopecia.

Investigators observed rapid, sustained clinical benefits after using vixarelimab in patients living with prurigo nodularis.

The highly selective oral TYK2 inhibitor met coprimary endpoints for sPGA 0/1 and PASI 75 at week 16 versus placebo in the phase 3 Latitude studies.

In this episode, a panel of dermatologists join to discuss the impact of the Boards University educational initiative for residents and early-career physicians.

Topline findings from the phase 2b REZOLVE-AA trial highlight the efficacy of rezpegaldesleukin in severe-to-very-severe alopecia areata.

This December 16 episode features a discussion of winter skin concerns and seasonal dermatologic challenges impacting patients with skin of color.

Investigators highlighted patterns of addictive behavior among those with chronic skin diseases in European tertiary dermatology centers.

Prurigo nodularis was shown to be linked with a significantly increased risk of malignancy, especially with cutaneous cancers.

Vanda Pharmaceuticals submitted a BLA to the FDA for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP).

Investigators compared the 2-year drug survival rates of biologics and JAKi in atopic dermatitis, in addition to evaluating associated predictors.

Phase 2b REZOLVE-AD trial data show rezpegaldesleukin improves skin symptoms and asthma control in adults with moderate-to-severe atopic dermatitis.

In this survey, investigators evaluated patients’ comprehension of frequently used cutaneous oncology-related words and looked at factors impacting their comprehension.

The phase 3 DISCREET study explored the safety and efficacy of apremilast in treating patients with moderate to severe genital psoriasis over 32 weeks.

The FDA has announced a proposal to include bemitrizinol to its list of allowable active ingredients to include in sunscreens.

In this interview, Serrao discusses the significance of the phase 2 INTEGUMENT-INFANT study, assessing once-daily roflumilast (Zoryve) cream 0.05% in infants with atopic dermatitis.

From diagnosis, investigators sought to explore psoriasis characteristics, patient demographics, patterns of treatment, and disease progression.

Explore the evolving role of AI in dermatology, balancing its benefits with concerns over accuracy, bias, and the human touch in patient care.

This analysis suggests a potential causal association between psoriasis and depression, highlighting the need for mental health screening in patients with psoriasis.

This study aimed to compare the efficacy and safety of monoclonal antibodies (mAb) for moderate-to-severe atopic dermatitis.

Investigators evaluated current prescription patterns for systemic HS medications among European HS specialists and opinions on criteria for biologic upgrades.

This systematic review and meta-analysis looked at research on the efficacy and safety of topical roflumilast 0.3% in patients with plaque psoriasis.

This FDA News Month in Review provides a round-up of regulatory decisions from November 2025.

This randomized study explored a lower-cost, ambient-light, nonpolarized dermatoscope and its clinical utility in patient-performed teledermoscopy.